Drug Trial Radar · NCT02932774
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
Last checked: Nov 20, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
683
Actual
Start
Mar 2001
Primary completion
Jul 2001
Study completion Jul 2001
Sponsor
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products WorldwideJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Oct 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.
Conditions
- Allergic Rhinitis
- Hay Fever
- SAR
- Rhinitis, Allergic, Seasonal
Interventions
CetirizineDrug
Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
LoratadineDrug
Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
PlaceboOther
Placebo syrup once daily before 10:00 AM for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to the Overall endpoint in the subject 24-hour reflective total symptom severity complex (TSSC) scoreTime frame: 2 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.